• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of pnasPNASInfo for AuthorsSubscriptionsAboutThis Article
Proc Natl Acad Sci U S A. Jul 1980; 77(7): 3957–3961.
PMCID: PMC349746

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.

Abstract

Mevinolin, a fungal metabolite, was isolated from cultures of Aspergillus terreus. The structure and absolute configuration of mevinolini and its open acid form, mevinolinic acid, were determined by a combination of physical techniques. Mevinolin was shown to be 1,2,6,7,8,8a-hexahydro-beta, delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1-naphthalene-hepatanoic acid delta-lactone. Mevinolin in the hydroxy-acid form, mevinolinic acid, is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase [mevalonate: NADP+ oxidoreductase (CoA-acylating), EC 1.1.1.34]; its Ki of 0.6 nM can be compared to 1.4 nM for the hydroxy acid form of the previously described related inhibitor, ML-236B (compactin, 6-demethylmevinolin). In the rat, orally administered sodium mevinolinate was an active inhibitor of cholesterol synthesis in an acute assay (50% inhibitory dose = 46 microgram/kg). Furthermore, it was shown that mevinolin was an orally active cholesterol-lowering agent in the dog. Treatment of dogs for 3 weeks with mevinolin at 8 mg/kg per day resulted in a 29.3 +/- 2.5% lowering of plasma cholesterol.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971 Jan;74(1):1–12. [PubMed]
  • Stamler J. Dietary and serum lipids in the multifactorial etiology of atherosclerosis. Arch Surg. 1978 Jan;113(1):21–25. [PubMed]
  • Grundy SM. Cholesterol metabolism in man. West J Med. 1978 Jan;128(1):13–25. [PMC free article] [PubMed]
  • Rodwell VW, Nordstrom JL, Mitschelen JJ. Regulation of HMG-CoA reductase. Adv Lipid Res. 1976;14:1–74. [PubMed]
  • Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo) 1976 Dec;29(12):1346–1348. [PubMed]
  • Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 1976 Dec 31;72(2):323–326. [PubMed]
  • Brown MS, Faust JR, Goldstein JL, Kaneko I, Endo A. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem. 1978 Feb 25;253(4):1121–1128. [PubMed]
  • Tanzawa K, Endo A. Kinetic analysis of the reaction catalyzed by rat-liver 3-hydroxy-3-methylglutaryl-coenzyme-A reductase using two specific inhibitors. Eur J Biochem. 1979 Jul;98(1):195–201. [PubMed]
  • Brown AG, Smale TC, King TJ, Hasenkamp R, Thompson RH. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J Chem Soc Perkin 1. 1976;(11):1165–1170. [PubMed]
  • Kaneko I, Hazama-Shimada Y, Endo A. Inhibitory effects on lipid metabolism in cultured cells of ML-236B, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase. Eur J Biochem. 1978 Jun 15;87(2):313–321. [PubMed]
  • Bensch WR, Ingebritsen TS, Diller ER. Lack of correlation between the rate of cholesterol biosynthesis and the activity of 3-hydroxy-3-methylgutaryl coenzyme A reductase in rats and in fibroblasts treated with ML-236B. Biochem Biophys Res Commun. 1978 May 15;82(1):247–254. [PubMed]
  • Doi O, Endo A. Specific inhibition of desmosterol synthesis by ML--236B in mouse LM cells grown in suspension in a lipid-free medium. Jpn J Med Sci Biol. 1978 Jun;31(3):225–233. [PubMed]
  • Endo A, Tsujita Y, Kuroda M, Tanzawa K. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Biochem. 1977 Jul 1;77(1):31–36. [PubMed]
  • Endo A, Tsujita Y, Kuroda M, Tanzawa K. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta. 1979 Nov 21;575(2):266–276. [PubMed]
  • Tsujita Y, Kuroda M, Tanzawa K, Kitano N, Endo A. Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Atherosclerosis. 1979 Mar;32(3):307–313. [PubMed]
  • Kuroda M, Tsujita Y, Tanzawa K, Endo A. Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Lipids. 1979 Jun;14(6):585–589. [PubMed]
  • Yamamoto A, Sudo H, Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis. 1980 Mar;35(3):259–266. [PubMed]
  • Heller RA, Shrewsbury MA. 3-Hydroxy-3-methylglutaryl coenzyme A reductase from rat liver. Its purification, properties, and immunochemical studies. J Biol Chem. 1976 Jun 25;251(12):3815–3822. [PubMed]
  • Kleinsek DA, Ranganathan S, Porter JW. Purification of 3-hydroxy-3-methylglutaryl-coenzyme A reductase from rat liver. Proc Natl Acad Sci U S A. 1977 Apr;74(4):1431–1435. [PMC free article] [PubMed]
  • Beg ZH, Stonik JA, Brewer HB., Jr Purification and characterization of 3-hydroxy-3-methylglutaryl coenzyme A reductase from chicken liver. FEBS Lett. 1977 Aug 1;80(1):123–129. [PubMed]
  • ABEL LL, LEVY BB, BRODIE BB, KENDALL FE. A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem. 1952 Mar;195(1):357–366. [PubMed]
  • DIXON M. The determination of enzyme inhibitor constants. Biochem J. 1953 Aug;55(1):170–171. [PMC free article] [PubMed]
  • Reichl D, Myant NB, Pflug JJ. Concentration of lipoproteins containing apolipoprotein B in human peripheral lymph. Biochim Biophys Acta. 1977 Oct 24;489(1):98–105. [PubMed]
  • Endo A. Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo) 1979 Aug;32(8):852–854. [PubMed]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...